Comparing treatments for advanced head and neck cancer
Part of Cancer clinical trials.
This trial tests a new combination of treatments for head and neck cancer that has returned or spread and can't be cured with local therapy. It compares a standard chemotherapy with or without an additional drug to see which is more effective and safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have head and neck cancer (in the mouth, throat, or voice box) that has returned or spread and can't be removed with surgery or treated with radiation.
- You have not had any prior treatment for this stage of cancer, unless you had a break of at least 12 months after a previous immunotherapy.
- You have at least one tumor that can be measured on a scan.
- You are generally able to care for yourself (ECOG score 0 or 1).
- If your cancer is in the oropharynx (back of the throat), you must have a test result for HPV (a virus linked to some throat cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two immunotherapy drugs (ivonescimab and pembrolizumab) given with standard chemotherapy before and possibly after surgery for advanced head and neck cancer that can be removed. The aim is to see which drug is better at shrinking the tumor and improving outcomes.
This trial is testing a new combination treatment, SYS6010 plus enlonstobart, for people with head and neck squamous cell carcinoma that has come back or spread. It aims to see if this combination works better than enlonstobart alone.
This study tests a combination of two medications—cetuximab (a targeted antibody) and either pembrolizumab or finotonlimab (immunotherapies)—along with chemotherapy, for advanced head and neck cancer that has spread or come back. The goal is to see if this combination helps shrink tumors and improve survival compared to standard treatment.
This trial tests a combination of re-radiation and chemotherapy with the immunotherapy drug pembrolizumab for people whose head and neck cancer has come back after earlier treatment. It compares this approach to standard immunotherapy or chemo-immunotherapy, and may offer a new option for patients whose cancer has a specific marker (PD-L1).
This trial tests a new way to give chemotherapy (pulsed doses) together with pembrolizumab (an immunotherapy) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination works better than standard approaches.
This trial tests two different drug combos—one using an EGFR-targeted therapy alone, the other adding an immunotherapy—before standard chemoradiation for locally advanced head and neck cancer. The goal is to see which approach works better without prior treatment.
Hear when a new Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.